Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, according to data from the Financial Conduct Authority, the FT report said.

For Soroban Capital Partners founder Eric Mandelblatt, the future growth of stock-picking hedge funds won’t come from hedging. “Where the world is heading, I think long-short will struggle to be a ...